Advancis checks its pulse

About a year to the day since going public, drug delivery company Advancis Pharmaceutical Corp. lost its anchor partner in GlaxoSmithKline plc and more than 60% of its market value. AVNC is now hoping investors will wait until the first half of 2005 for data from its Phase III trial of a pulsatile once daily formulation of amoxicillin for proof that AVNC's Pulsys technology is commercially

Read the full 667 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE